Back to News
Market Impact: 0.25
Revolution Medicines Stock Has Surged 124% This Year — Analyst Sees More Room to Grow
Source: benzinga.com
Analyst InsightsHealthcare & BiotechCompany Fundamentals
William Blair initiated coverage of Revolution Medicines with an Outperform rating and a $226 price forecast, citing growth opportunities beyond pancreatic cancer. The article provides no current share price or quantified upside.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.30
Ticker Sentiment
RVMD0.65
More News
- William Blair initiates Revolution stock with outperform on RAS franchise
- Here are Friday's biggest analyst calls: Nvidia, SpaceX, Tesla, Apple, Mobileye, EchoStar, Toll Brothers & more
- Why did CoreWeave stock get crushed this week? Look to this corner of the debt market for clues
- AI stock sell-off ramps up over debt-fueled data center spending fears: ‘Full-blown crisis of confidence'
- All the news about the iPhone Duo
- The Tesla Roadster should go into production in 2028, but don't get your hopes up